FindTrial
Sign In

pralsetinib (BLU-667)

DRUG2 trials

Sponsors

Hoffmann-La Roche, Blueprint Medicines Corporation

Conditions

AdenocarcinomaAdenocarcinoma, PapillaryBronchial NeoplasmsCarcinomaCarcinoma, BronchogenicCarcinoma, NeuroendocrineCarcinoma, Non-Small-Cell LungColonic Diseases

Phase 1

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
CompletedNCT03037385
Hoffmann-La RocheAdenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms +37
Start: 2017-03-17End: 2024-03-21Updated: 2025-05-31

Unknown Phase

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
NCT04204928
Blueprint Medicines CorporationMedullary Thyroid Cancer, Non-Small Cell Lung Cancer
Updated: 2021-08-13

Related Papers

Efficacy and safety of pralsetinib in advanced or metastatic <i>RET</i> -altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.
Journal of Clinical Oncology2026-05-27
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer
Journal of Clinical Oncology2026-03-26
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.
2025-07-23
Efficacy and safety of pralsetinib in patients with advanced <i>RET</i> -fusion-positive NSCLC: Final data from the phase 1/2 ARROW study.
Journal of Clinical Oncology2025-05-282 citations
Efficacy and safety of pralsetinib in <i>RET</i> fusion-positive solid tumors: Final data from the ARROW trial.
Journal of Clinical Oncology2025-05-28
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients
Endocrine Related Cancer2024-01-236 citations
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Thyroid2023-11-2744 citations
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
2023-11-0720 citations
Pralsetinib in Patients with RET Fusion–Positive Non-Small-Cell Lung Cancer: A Plain Language Summary of the ARROW Study
Future Oncology2023-11-02
Efficacy and safety of pralsetinib in patients with advanced <i>RET</i> fusion‐positive non–small cell lung cancer
Cancer2023-06-0619 citations
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
2022-08-12164 citations
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.
2022-06-1754 citations
Pralsetinib in patients (pts) with advanced or metastatic <i>RET</i>-altered thyroid cancer (TC): Updated data from the ARROW trial.
Journal of Clinical Oncology2022-06-0110 citations
AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with <i>RET</i> fusion–positive advanced/metastatic NSCLC.
Journal of Clinical Oncology2022-06-016 citations
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
2021-06-09290 citations
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
2021-06-09243 citations
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or Fusions
Clinical Cancer Research2021-05-2798 citations
Safety and efficacy of pralsetinib in patients with advanced <i>RET</i> fusion-positive non-small cell lung cancer: Update from the ARROW trial.
Journal of Clinical Oncology2021-05-2011 citations
Clinical activity and safety of the RET inhibitor pralsetinib in patients with <i>RET</i> fusion-positive solid tumors: Update from the ARROW trial.
Journal of Clinical Oncology2021-05-207 citations
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with <i>RET</i> fusion–positive solid tumors.
Journal of Clinical Oncology2021-01-2043 citations

9 more papers not shown